Note:This document has been translated from the Japanese-language original (hereinafter, the “original”) for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail.

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS]

July 31, 2026

Company Name:	SUMITOMO PHARMA CO., LTD.
Stock Exchange Listings:	Tokyo
Security Code Number:	4506 (URL https://www.sumitomo-pharma.com)
Representative:	Toru Kimura, Representative Director, President and Chief Executive Officer
Contact:	Megumi Maruyama, Vice President, Head of Corporate Communications
Telephone:	06-6203-5321
Starting Date of Dividend Payments:	—
Preparation of Supplementary Financial Data for Quarterly Financial Results:	Yes
Information Meeting for Quarterly Financial Results to be held:	Yes (for institutional investors, analysts and the press)

(Note: All amounts are rounded to the nearest million JPY)

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (April 1, 2026 to June 30, 2026)

(1) Results of Operations

(% represents changes from the previous year)

	Revenue		Core operating profit		Operating profit		Net profit		Net profit attributable to owners of the parent		Total comprehensive income	
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%
Three months ended June 30, 2026	129,495	19.9	18,134	(11.0)	18,188	(10.8)	16,997	51.7	16,997	51.7	18,910	180.0
Three months ended June 30, 2025	108,002	19.1	20,365	—	20,400	—	11,206	(29.7)	11,206	(29.7)	6,754	40.9

Reference: Profit before taxes Three months ended June 30, 2026: 18,295 million JPY
Three months ended June 30, 2025: 11,932 million JPY

“Core operating profit” is calculated by deducting certain items from operating profit.

	Basic earnings per share	Earnings per share (diluted)
	JPY	JPY
Three months ended June 30, 2026	39.02	—
Three months ended June 30, 2025	28.21	—

(2) Financial Position

	Total assets	Net assets	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets	Equity attributable to owners of the parent per share
	Millions of JPY	Millions of JPY	Millions of JPY	%	JPY
As of June 30, 2026	844,883	408,555	408,555	48.4	910.75
As of March 31, 2026	804,571	292,467	292,467	36.4	736.16

2. Dividends

	Dividends per share				
	1st quarter	2nd quarter	3rd quarter	Year-End	Annual
	JPY	JPY	JPY	JPY	JPY
Fiscal year ended March 31, 2026	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2027	—				
Fiscal year ending March 31, 2027 (Forecasts)		—	—	—	—

Note:Revision of dividend forecasts from the latest announcement: None
While the Company’s Articles of Incorporation specify the end of the second quarter and the year-end as dividend record dates, a forecast for dividend amounts for the fiscal year ending March 31,2027 has not been established as of the date of this release.

3. Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(% represents changes from the previous year)

	Revenue		Core operating profit		Operating profit		Net profit attributable to owners of the parent		Earnings per share
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	JPY
Half-Year ending September 30, 2026	251,000	10.5	30,000	(68.8)	30,000	(68.8)	26,000	(73.7)	58.80
Fiscal year ending March 31, 2027	540,000	19.1	91,000	(14.1)	90,000	(16.2)	77,000	(27.9)	172.89

Note:Revision of consolidated financial forecasts from the latest announcement: Yes
In the “Summary of Consolidated Financial Results for the Year Ended March 31, 2026 [IFRS]” published on May 13, 2026, we did not announce our forecast for consolidated financial results for the half-year ending September 30, 2026, but we have now announced it as above. There are no changes to the consolidated financial forecast for the fiscal year ending March 31, 2027.

*** Notes:**

(1) Significant changes in the scope of consolidation during the period: None
(New: None)
(Excluded: None)

(2) Changes in accounting policies, accounting estimates
① Changes in accounting policy required by IFRS: Yes
② Changes in accounting policy due to other reasons: None
③ Changes in accounting estimates: None
Note: For details, please refer to "2. Condensed Consolidated Financial Statements and Major Notes (5) Notes to Condensed Consolidated Financial Statements (Material Accounting Policies)" on page 12 of Attachment Documents.

(3) Number of shares issued (Common stock)
① Number of shares issued (Including treasury stock) at end of period

As of June 30, 2026	449,204,554	shares
As of March 31, 2026	397,900,154	shares

② Number of treasury stock at the end of period

As of June 30, 2026	611,326	shares
As of March 31, 2026	611,105	shares

③ Average number of shares outstanding during the period

Three months ended June 30, 2026	435,626,295	shares
Three months ended June 30, 2025	397,289,812	shares

** Review of the Japanese language-originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)*

** Explanation for Appropriate Use of Forecasts and Other Notes:*

- This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein. Please refer to page 4 of Attachment Documents, "1. Qualitative Information of Financial Results for the Three Months Ended June 30, 2026 (5) Consolidated Financial Forecasts".

- Information concerning pharmaceuticals and other products (including those under development) contained herein is not intended as advertising or as medical advice.

- Supplementary financial data and the presentation materials for the earnings presentation are disclosed together with this summary.

- The Company holds an earnings presentation for institutional investors, analysts and the press on Friday, July 31, 2026. The audio of the presentation will be posted on its website promptly after the presentation.

【Attachment Documents】

1. Qualitative Information of Financial Results for the Three Months Ended June 30, 2026

Forward-looking statements contained herein are based on the Group's judgments in light of information available as of the last day of the three-month period.

(1) Business Results

(About the performance indicator of "Core operating profit")
With the adoption of International Financial Reporting Standards (IFRS), the Group has set "core operating profit" which shows the Group's profitability as its original performance indicator.
"Core operating profit" is calculated by deducting certain items from operating profit. The deduction items mainly include impairment losses, business structure improvement expenses, and changes in fair value of contingent consideration.

Highlights of the Group's consolidated financial results for the first three months of the fiscal year ending March 31, 2027 are as follows:

(Billions of JPY)

	Three months ended June 30, 2025	Three months ended June 30, 2026	Change	Change %
Revenue	108.0	129.5	21.5	19.9
Core operating profit	20.4	18.1	(2.2)	(11.0)
Operating profit	20.4	18.2	(2.2)	(10.8)
Profit before taxes	11.9	18.3	6.4	53.3
Net profit attributable to owners of the parent	11.2	17.0	5.8	51.7

■ Revenue increased by 19.9% year-on-year to 129.5 billion JPY.

Revenue increased by 21.5 billion JPY year-on-year to 129.5 billion JPY. The increase resulted primarily from expanded sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (therapeutic agent for overactive bladder) in the U.S. These increases more than offset the decrease resulting from the partial transfer of the Asian business in the previous fiscal year.

[U.S.]
Revenue increased by 24.4 billion JPY year-on-year to 94.3 billion JPY. Although sales of APTIOM® (antiepileptic treatment) decreased due to the loss of exclusivity, revenue increased primarily due to expanded sales of ORGOVYX® and GEMTESA®.

[Japan]
Revenue increased by 1.0 billion JPY year-on-year to 22.2 billion JPY. Although sales of Equa® and EquMet® (both therapeutic agents for type 2 diabetes) decreased following the termination of sales by the Company, revenue increased primarily owing to the commencement of sales of XEPLION® and XEPLION TRI® (both long-acting antipsychotic medications) by the Company and sales growth of TWYMEEG® (therapeutic agent for type 2 diabetes).

[Others]
Revenue decreased by 3.9 billion JPY year-on-year to 13.0 billion JPY. Although export sales to Europe increased, revenue decreased primarily due to the impact of the partial transfer of the Asian business in the previous fiscal year.

■ Core operating profit decreased by 11.0% year-on-year to 18.1 billion JPY.

Although revenue increased, the gross profit margin declined primarily due to changes in the product mix resulting from the partial transfer of the Asian business. In addition, selling, general and administrative expenses increased primarily due to the increase in sales promotion expenses aimed at expanding revenue in the U.S. Research and development expenses also increased due to the increased momentum in clinical studies in the oncology area and the advancement of clinical studies in the psychiatry and neurology area. As a result, core operating profit decreased.

■ Operating profit decreased by 10.8% year-on-year to 18.2 billion JPY.

Operating profit decreased due to the decline in core operating profit.

■ **Profit before taxes increased by 53.3% year-on-year to 18.3 billion JPY.**

Despite the decrease in operating profit, profit before taxes increased, primarily owing to foreign exchange gains recorded during the reporting period, compared with foreign exchange losses recorded in the corresponding period of the previous fiscal year.

■ **Net profit attributable to owners of the parent increased by 51.7% year-on-year to 17.0 billion JPY.**

Net profit attributable to owners of the parent increased, mainly due to the increase in profit before taxes.

Previously, the Group disclosed its consolidated financial statements based on geographical reportable segments. Given the increasingly global nature of its business operations, the Group changed to a single segment, Pharmaceutical Business, beginning with the three months ended June 30, 2026. Accordingly, business results based on the Group's former reportable segments have been omitted. For details, please refer to “2. Condensed Consolidated Financial Statements and Major Notes (5) Notes to Condensed Consolidated Financial Statements (Segment Information)”.

(2) Financial Condition

Total assets increased by 40.3 billion JPY from the previous fiscal year-end to 844.9 billion JPY.

Non-current assets increased by 2.1 billion JPY from the previous fiscal year-end, as goodwill increased due to the effects of foreign currency translation amid the ongoing depreciation of the yen, and investments accounted for using the equity method increased mainly due to additional investment in RACTHERA Co., Ltd., a company collaborating with the Group in the regenerative cell medicine business.

Current assets increased by 38.2 billion JPY from the previous fiscal year-end as a result of an increase in cash and cash equivalents.

Liabilities decreased by 75.8 billion JPY to 436.3 billion JPY as a result of decreases in borrowings and other current liabilities.

Total equity increased by 116.1 billion JPY from the previous fiscal year-end to 408.6 billion JPY as a result of increases in share capital and capital surplus following the public offering conducted during the three months ended June 30, 2026, and an increase in retained earnings following the recording of net profit.

The ratio of equity attributable to owners of the parent to total assets at the end of the quarterly accounting period was 48.4%.

(3) Cash Flows

Cash flows used in operating activities amounted to 7.4 billion JPY, reflecting a year-on-year increase in net cash outflow of 7.3 billion JPY. This was because of increases in trade and other receivables and decreases in trade and other payables, as well as decreases in other current liabilities included in others, net, which more than offset increases in net profit and other financial liabilities.

Cash flows provided by investing activities amounted to 0.0 billion JPY, reflecting a year-on-year increase in net cash inflow of 4.4 billion JPY. This was primarily due to an increase in proceeds from sales and redemption of investments.

Cash flows provided by financing activities amounted to 39.2 billion JPY, reflecting a year-on-year increase in net cash inflow of 35.9 billion JPY. This was primarily due to proceeds from the issuance of shares and repayments of long-term borrowings during the reporting period.

After adding the translation adjustments for cash and cash equivalents to the above cash flows, the balance of cash and cash equivalents at the end of the quarterly accounting period was 76.6 billion JPY, which represents an increase of 32.3 billion JPY from the previous fiscal year-end.

(4) Research and Development Activities

Research and development expenses for the three months ended June 30, 2026 amounted to 11.4 billion JPY (increased by 39.8% year-on-year). Please note that, excluding the business structure improvement expenses recorded in the corresponding period of the previous fiscal year, research and development expenses on a core basis would have increased by 41.2% year-on-year.

In the oncology area, a pivotal Phase 2 monotherapy study of enzomenib (product code: DSP-5336) in patients with acute myeloid leukemia with NPM1 mutation was initiated in April 2026. In June 2026, enrollment of the number of patients required for the interim analysis was completed in a pivotal Phase 2 monotherapy study of enzomenib in patients with acute leukemia with KMT2A rearrangement.

(5) Consolidated Financial Forecasts

Based on the consolidated financial results for the first quarter and the outlook for the second quarter, the Company hereby announces its consolidated financial forecast for the first half of the fiscal year, as follows:
There is no change to the full-year consolidated financial forecast announced at the beginning of the fiscal year.

Forecasts of Consolidated Financial Results for the Half-Year Ending September 30, 2026
(April 1, 2026 to September 30, 2026)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
	Millions of JPY	Millions of JPY	Millions of JPY	Millions of JPY	JPY
Previous Forecasts (A)	—	—	—	—	—
Revised Forecast (B)	251,000	30,000	30,000	26,000	58.80
Variance in amount (B-A)	—	—	—	—	—
Variance in percent (%)	—	—	—	—	—
[Reference] Year ended September 30, 2025	227,122	96,084	96,157	98,860	248.84

Note: "Core operating profit" is calculated by deducting certain items from operating profit. The deduction items mainly include impairment losses, business structure improvement expenses and changes in fair value of contingent consideration.

The exchange rate (average exchange rates) is assumed to be 155.00 JPY against 1 USD, the same as the full-year forecast announced at the beginning of the fiscal year.

Note: Consolidated Financial Forecasts above are based on the certain assumptions considered reasonable and on information available at the time of disclosure of such statements. Accordingly, actual financial results may differ from those presented herein caused by various factors thereafter.

2. Condensed Consolidated Financial Statements and Major Notes

(1) Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of Comprehensive Income

Condensed Consolidated Statement of Profit or Loss

(Millions of JPY)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Revenue	108,002	129,495
Cost of sales	44,112	61,414
Gross profit	63,890	68,081
Selling, general and administrative expenses	35,657	39,237
Research and development expenses	8,175	11,430
Other income	1,346	468
Other expenses	366	131
Share of profit (loss) of investments accounted for using the equity method	(638)	437
Operating profit	20,400	18,188
Finance income	585	2,200
Finance costs	9,053	2,093
Profit before taxes	11,932	18,295
Income tax expenses	726	1,298
Net profit	11,206	16,997
Net profit attributable to:		
Owners of the parent	11,206	16,997
Net profit	11,206	16,997
Earnings per share (JPY)		
Basic earnings per share	28.21	39.02

Condensed Consolidated Statement of Comprehensive Income

(Millions of JPY)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net profit	11,206	16,997
Other comprehensive income		
Items that will not be reclassified to profit or loss:		
Changes in financial assets measured at fair value through other comprehensive income	(217)	(194)
Share of other comprehensive income of investments accounted for using the equity method	—	(40)
Items that may be reclassified subsequently to profit or loss:		
Changes in financial assets measured at fair value through other comprehensive income	23	—
Exchange differences on translation of foreign operations	(4,258)	1,796
Share of other comprehensive income of investments accounted for using the equity method	—	351
Total other comprehensive income	(4,452)	1,913
Total comprehensive income	6,754	18,910
Total comprehensive income attributable to:		
Owners of the parent	6,754	18,910
Total comprehensive income	6,754	18,910

(2) Condensed Consolidated Statement of Financial Position

(Millions of JPY)

	As of March 31, 2026	As of June 30, 2026
Assets		
Non-current assets		
Property, plant and equipment	44,231	44,511
Goodwill	211,098	214,385
Intangible assets	160,474	157,358
Other financial assets	44,703	42,894
Income taxes receivable	7,234	7,347
Retirement benefit assets	19,463	19,682
Investments accounted for using the equity method	36,400	38,818
Other non-current assets	1,295	1,805
Deferred tax assets	421	601
Total non-current assets	525,319	527,401
Current assets		
Inventories	85,414	79,675
Trade and other receivables	131,414	139,508
Other financial assets	5,327	7,412
Income taxes receivable	3,273	3,277
Other current assets	9,514	10,970
Cash and cash equivalents	44,310	76,640
Total current assets	279,252	317,482
Total assets	804,571	844,883

(Millions of JPY)

	As of March 31, 2026	As of June 30, 2026
Liabilities and equity		
Liabilities		
Non-current liabilities		
Bonds and borrowings	179,056	119,658
Other financial liabilities	16,563	17,004
Retirement benefit liabilities	5,663	5,659
Other non-current liabilities	23,486	16,448
Deferred tax liabilities	15,836	15,686
Total non-current liabilities	240,604	174,455
Current liabilities		
Borrowings	38,130	41,000
Trade and other payables	56,698	48,864
Other financial liabilities	35,217	38,618
Income taxes payable	1,120	1,898
Provisions	89,566	96,210
Other current liabilities	50,769	35,283
Total current liabilities	271,500	261,873
Total liabilities	512,104	436,328
Equity		
Share capital	22,400	71,321
Capital surplus	—	48,258
Treasury shares	(684)	(685)
Retained earnings	158,981	176,508
Other components of equity	111,770	113,153
Equity attributable to owners of the parent	292,467	408,555
Total equity	292,467	408,555
Total liabilities and equity	804,571	844,883

(3) Condensed Consolidated Statement of Changes in Equity

(Millions of JPY)

	Equity attributable to owners of the parent						
					Other components of equity		
	Share capital	Capital surplus	Treasury shares	Retained earnings	Changes in financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations	Total
Balance as of April 1, 2025	22,400	–	(682)	46,784	9,306	88,219	97,525
Net profit	–	–	–	11,206	–	–	–
Other comprehensive income	–	–	–	–	(194)	(3,520)	(3,714)
Total comprehensive income	–	–	–	11,206	(194)	(3,520)	(3,714)
Issuance of new shares	–	–	–	–	–	–	–
Purchase of treasury shares	–	–	(0)	–	–	–	–
Reclassification from other components of equity to retained earnings	–	–	–	(66)	66	–	66
Total transactions with owners	–	–	(0)	(66)	66	–	66
Balance as of June 30, 2025	22,400	–	(682)	57,924	9,178	84,699	93,877
Balance as of April 1, 2026	22,400	–	(684)	158,981	8,768	103,002	111,770
Net profit	–	–	–	16,997	–	–	–
Other comprehensive income	–	–	–	–	(234)	2,147	1,913
Total comprehensive income	–	–	–	16,997	(234)	2,147	1,913
Issuance of new shares	48,921	48,258	–	–	–	–	–
Purchase of treasury shares	–	–	(1)	–	–	–	–
Reclassification from other components of equity to retained earnings	–	–	–	530	(530)	–	(530)
Total transactions with owners	48,921	48,258	(1)	530	(530)	–	(530)
Balance as of June 30, 2026	71,321	48,258	(685)	176,508	8,004	105,149	113,153

(Millions of JPY)

	Equity attributable to owners of the parent		Total equity
	Other comprehensive income associated with assets held for sale	Total	
Balance as of April 1, 2025	3,452	169,479	169,479
Net profit	—	11,206	11,206
Other comprehensive income	(738)	(4,452)	(4,452)
Total comprehensive income	(738)	6,754	6,754
Issuance of new shares	—	—	—
Purchase of treasury shares	—	(0)	(0)
Reclassification from other components of equity to retained earnings	—	—	—
Total transactions with owners	—	(0)	(0)
Balance as of June 30, 2025	2,714	176,233	176,233

Balance as of April 1, 2026	—	292,467	292,467
Net profit	—	16,997	16,997
Other comprehensive income	—	1,913	1,913
Total comprehensive income	—	18,910	18,910
Issuance of new shares	—	97,179	97,179
Purchase of treasury shares	—	(1)	(1)
Reclassification from other components of equity to retained earnings	—	—	—
Total transactions with owners	—	97,178	97,178
Balance as of June 30, 2026	—	408,555	408,555

(4) Condensed Consolidated Statement of Cash Flows

(Millions of JPY)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Net profit	11,206	16,997
Depreciation and amortization	5,203	4,899
Changes in fair value of financial assets and liabilities related to contingent consideration arrangements	(139)	(281)
Interest and dividend income	(362)	(460)
Interest expenses	1,817	1,609
Income tax expenses	726	1,298
(Increase) decrease in trade and other receivables	(11,719)	(7,277)
(Increase) decrease in inventories	2,142	5,878
Increase (decrease) in trade and other payables	1,409	(8,728)
Increase (decrease) in unearned revenue	(3,155)	(3,483)
Increase (decrease) in other financial liabilities	(209)	6,534
Increase or decrease in retirement benefit assets and liabilities	(172)	(223)
Increase (decrease) in provisions	2,110	5,158
Others, net	(7,836)	(28,855)
Subtotal	1,021	(6,934)
Interest received	231	253
Dividends received	124	199
Interest paid	(649)	(516)
Income taxes paid	(919)	(445)
Net cash provided by (used in) operating activities	(192)	(7,443)
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,474)	(663)
Proceeds from sales of property, plant and equipment	333	33
Purchase of intangible assets	(977)	(363)
Purchase of shares of subsidiaries and associates	(2,338)	(1,670)
Purchase of investments	(462)	(586)
Proceeds from sales and redemption of investments	108	2,786
Proceeds from settlement of contingent consideration	—	512
Proceeds from loss of control of subsidiaries	51	—
Others, net	445	—
Net cash provided by (used in) investing activities	(4,314)	49
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	3,970	2,870
Repayments of long-term borrowings	—	(60,000)
Repayments of lease liabilities	(670)	(505)
Proceeds from issuance of shares	—	96,875
Dividends paid	(1)	(1)
Others, net	(80)	(87)
Net cash provided by (used in) financing activities	3,219	39,152
Net increase (decrease) in cash and cash equivalents	(1,287)	31,758
Cash and cash equivalents at beginning of year (Condensed Consolidated Statement of Financial Position)	23,116	44,310
Reversal of cash and cash equivalents included in assets held for sale	13,172	—
Cash and cash equivalents at beginning of year	36,288	44,310
Effect of exchange rate changes on cash and cash equivalents	(788)	572
Cash and cash equivalents at end of period	34,213	76,640
Increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	(13,760)	—
Cash and cash equivalents at end of period (Condensed Consolidated Statement of Financial Position)	20,453	76,640

(5) Notes to Condensed Consolidated Financial Statements

(Framework of Financial Report)

The Group's Condensed Consolidated Financial Statements have been prepared in accordance with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Financial Statements of Tokyo Stock Exchange, Inc. (with the omission of certain disclosures permitted under Article 5, Paragraph 5 of those Standards).

(Notes regarding Going Concern Assumption)

Not applicable.

(Material Accounting Policies)

The material accounting policies applied to the Condensed Consolidated Financial Statements are the same as those for the previous fiscal year's consolidated financial statements, except for the accounting standard provided below.

Income tax expenses for the three months ended June 30, 2026 are calculated based on the estimated average annual effective tax rate.

New or amended Standards and Interpretations		Overview of introduction or amendment
IFRS 7	Financial Instruments: Disclosures	Clarifications to the classification and measurement of financial instruments and disclosure requirements relating to investments in equity instruments
IFRS 9	Financial Instruments	

Beginning with the three months ended June 30, 2026, the Group has adopted the “Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 7 and IFRS 9)”. The adoption of the amendments to IFRS 7 and IFRS 9 does not have a material impact on the Group's Condensed Consolidated Financial Statements.

(Segment Information)

The Group has historically managed its business under three reportable segments (Japan, North America, and Asia), but beginning with the three months ended June 30, 2026, it manages its business as a single operating segment.

In the previous fiscal year, the Group transferred assets, including patent rights for the three key products in the U.S., from its wholly-owned subsidiaries, Sumitomo Pharma Switzerland GmbH and Urovant Sciences GmbH, to the Company, thereby establishing a structure under which the Company is directly involved in the business operations of these products. As a result, the Representative Director, President now makes decisions on the allocation of management resources and evaluates performance for the pharmaceutical business as a whole. Accordingly, the reportable segments have been consolidated into a single segment, Pharmaceutical Business, and disclosures of revenue and performance by the Group's former reportable segments have been omitted.

(Material Subsequent Event)

Not applicable.